Mavacamten History and Updates

130 events · 2018 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

FDA Approvals

Label Revisions

123

Trial Milestones

Pivotal Publications

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-15Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Mavacamten since 2018, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (4)

2025

Primary completionMavacamten Phase 3 Trial for Adolescent HCM Reaches Primary Completion· Nov 25, 2025
FDA approval (supplemental)Camzyos (Mavacamten) Receives FDA Supplemental Approval for Efficacy· Apr 17, 2025
Results postedMavacamten Phase 2a HFpEF Trial Shows Reductions in Cardiac Biomarkers· Mar 20, 2025
Primary completionMavacamten Phase 3 Trial for Non-Obstructive HCM Completes Primary Endpoint· Mar 6, 2025

Upcoming & expected milestones

Primary completionJul 1, 2026· ClinicalTrials.gov

Phase 4 primary completion: NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Primary completionJul 9, 2026· ClinicalTrials.gov

Phase 4 primary completion: NCT06112743

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Primary completionAug 31, 2026· ClinicalTrials.gov

Primary completion: NCT06023186

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Primary completionNov 30, 2026· ClinicalTrials.gov

Primary completion: NCT06146660

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Primary completionDec 14, 2026· ClinicalTrials.gov

Primary completion: NCT07557498

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Primary completionDec 31, 2026· ClinicalTrials.gov

Primary completion: NCT07541833

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Primary completionDec 31, 2026· ClinicalTrials.gov

Primary completion: NCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Primary completionApr 30, 2027· ClinicalTrials.gov

Primary completion: NCT05939700

Mavacamten Pregnancy Surveillance Program

Primary completionMay 31, 2027· ClinicalTrials.gov

NA primary completion: NCT07120776

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Primary completionMay 31, 2027· ClinicalTrials.gov

Primary completion: NCT07150299

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Primary completionDec 13, 2027· ClinicalTrials.gov

Phase 4 primary completion: NCT07004972

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Primary completionAug 22, 2028· ClinicalTrials.gov

Primary completion: NCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Primary completionOct 31, 2028· ClinicalTrials.gov

NA primary completion: NCT07120776

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Primary completionAug 17, 2029· ClinicalTrials.gov

Primary completion: NCT05489705

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receivi

Primary completionNov 30, 2029· ClinicalTrials.gov

Primary completion: NCT07383025

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Past events

2026

Trial registeredApr 29, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07557498

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Trial registeredApr 21, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07541833

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Trial registeredApr 14, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07529938

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

Trial startedFeb 5, 2026· ClinicalTrials.gov

Trial started: NCT07541833

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Trial registeredFeb 3, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07383025

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Primary completionFeb 1, 2026· ClinicalTrials.gov

NA primary completion: NCT06947590

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Trial registeredJan 23, 2026· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Primary completionJan 16, 2026· ClinicalTrials.gov

Phase 2/Phase 3 primary completion: NCT03723655

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Trial startedJan 15, 2026· ClinicalTrials.gov

Trial started: NCT07557498

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Trial startedJan 15, 2026· ClinicalTrials.gov

Trial started: NCT07361289

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Trial startedJan 1, 2026· ClinicalTrials.gov

Phase 4 trial started: NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

2025

Primary completionDec 1, 2025· ClinicalTrials.gov

NA primary completion: NCT06856265

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Primary completionNov 25, 2025· ClinicalTrials.gov

Phase 3 primary completion: NCT06253221

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedSep 30, 2025· ClinicalTrials.gov

NA trial started: NCT07120776

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Primary completionSep 29, 2025· ClinicalTrials.gov

Primary completion: NCT06372457

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive H

Trial registeredSep 11, 2025· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07168655

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Trial startedSep 5, 2025· ClinicalTrials.gov

Trial started: NCT07150299

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Trial startedSep 4, 2025· ClinicalTrials.gov

Phase 4 trial started: NCT07004972

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Trial registeredSep 2, 2025· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07150299

Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy

Trial registeredAug 13, 2025· ClinicalTrials.gov

NA trial registered on ClinicalTrials.gov: NCT07120776

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Trial registeredAug 6, 2025· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT07107373

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Trial registeredAug 5, 2025· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Trial registeredJun 4, 2025· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT07004972

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Primary completionMay 30, 2025· ClinicalTrials.gov

Primary completion: NCT07529938

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

Trial startedMay 21, 2025· ClinicalTrials.gov

Trial started: NCT07383025

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Trial registeredApr 27, 2025· ClinicalTrials.gov

NA trial registered on ClinicalTrials.gov: NCT06947590

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

Trial startedApr 20, 2025· ClinicalTrials.gov

NA trial started: NCT06947590

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy

FDA approval (supplemental)Apr 17, 2025· FDA

FDA approved supplemental application for Camzyos (mavacamten) — Efficacy (NDA 214998 S-10)

Sponsor: BRISTOL. Class: Efficacy.

Results postedMar 20, 2025· ClinicalTrials.gov

Trial results posted: NCT04766892

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Primary completionMar 6, 2025· ClinicalTrials.gov

Phase 3 primary completion: NCT05582395

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Trial registeredMar 4, 2025· ClinicalTrials.gov

NA trial registered on ClinicalTrials.gov: NCT06856265

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedFeb 26, 2025· ClinicalTrials.gov

NA trial started: NCT06856265

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Results postedJan 9, 2025· ClinicalTrials.gov

Trial results posted: NCT03496168

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

2024

Results postedDec 4, 2024· ClinicalTrials.gov

Trial results posted: NCT05414175

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Primary completionNov 12, 2024· ClinicalTrials.gov

Primary completion: NCT06338202

Real-World Effectiveness of Mavacamten in Canada

Results postedSep 19, 2024· ClinicalTrials.gov

Trial results posted: NCT05174416

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Trial registeredAug 13, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Trial registeredAug 12, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06549608

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Primary completionJul 26, 2024· ClinicalTrials.gov

Primary completion: NCT07107373

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Results postedJul 25, 2024· ClinicalTrials.gov

Trial results posted: NCT05135871

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Trial startedJul 24, 2024· ClinicalTrials.gov

Trial started: NCT06146660

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedJun 24, 2024· ClinicalTrials.gov

Trial started: NCT06338202

Real-World Effectiveness of Mavacamten in Canada

Primary completionJun 13, 2024· ClinicalTrials.gov

Phase 1 primary completion: NCT06211179

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5

Trial startedMay 10, 2024· ClinicalTrials.gov

Trial started: NCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Primary completionMay 6, 2024· ClinicalTrials.gov

Primary completion: NCT06549608

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

FDA approval (supplemental)Apr 30, 2024· FDA

FDA approved supplemental application for Camzyos (mavacamten) — Labeling (NDA 214998 S-9)

Sponsor: BRISTOL. Class: Labeling.

Trial startedApr 20, 2024· ClinicalTrials.gov

Trial started: NCT06549608

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Trial registeredApr 18, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06372457

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive H

Trial startedApr 17, 2024· ClinicalTrials.gov

Phase 3 trial started: NCT06253221

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial registeredMar 29, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06338202

Real-World Effectiveness of Mavacamten in Canada

Primary completionFeb 26, 2024· ClinicalTrials.gov

Phase 2 primary completion: NCT04766892

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Trial registeredFeb 12, 2024· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT06253221

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedJan 24, 2024· ClinicalTrials.gov

Phase 4 trial started: NCT06112743

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial registeredJan 18, 2024· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT06211179

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5

Trial startedJan 10, 2024· ClinicalTrials.gov

Phase 1 trial started: NCT06211179

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5

Trial startedJan 1, 2024· ClinicalTrials.gov

Trial started: NCT07529938

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

2023

Trial startedDec 22, 2023· ClinicalTrials.gov

Trial started: NCT07107373

A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

FDA approval (supplemental)Dec 19, 2023· FDA

FDA approved supplemental application for Camzyos (mavacamten) — REMS (NDA 214998 S-8)

Sponsor: BRISTOL. Class: REMS.

Trial startedDec 1, 2023· ClinicalTrials.gov

Trial started: NCT06372457

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive H

Trial registeredNov 27, 2023· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06146660

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Primary completionNov 27, 2023· ClinicalTrials.gov

Phase 3 primary completion: NCT05414175

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Trial startedNov 9, 2023· ClinicalTrials.gov

Trial started: NCT05939700

Mavacamten Pregnancy Surveillance Program

Primary completionNov 9, 2023· ClinicalTrials.gov

Phase 2 primary completion: NCT03496168

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Trial startedNov 3, 2023· ClinicalTrials.gov

Trial started: NCT06023186

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Trial registeredNov 1, 2023· ClinicalTrials.gov

Phase 4 trial registered on ClinicalTrials.gov: NCT06112743

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial registeredSep 5, 2023· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06023186

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Primary completionJul 25, 2023· ClinicalTrials.gov

Phase 1 primary completion: NCT05719805

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Trial registeredJul 11, 2023· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05939700

Mavacamten Pregnancy Surveillance Program

Primary completionJul 5, 2023· ClinicalTrials.gov

Phase 1 primary completion: NCT05658146

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

FDA approval (supplemental)Jun 15, 2023· FDA

FDA approved supplemental application for Camzyos (mavacamten) — Efficacy (NDA 214998 S-1)

Sponsor: BRISTOL. Class: Efficacy.

Primary completionMar 31, 2023· ClinicalTrials.gov

Primary completion: NCT07168655

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Results postedMar 7, 2023· ClinicalTrials.gov

Trial results posted: NCT04349072

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Primary completionMar 6, 2023· ClinicalTrials.gov

Phase 3 primary completion: NCT05174416

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Trial startedFeb 21, 2023· ClinicalTrials.gov

Trial started: NCT07168655

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Trial startedFeb 20, 2023· ClinicalTrials.gov

Phase 1 trial started: NCT05719805

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

Trial registeredFeb 9, 2023· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05719805

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

FDA approval (supplemental)Jan 13, 2023· FDA

FDA approved supplemental application for Camzyos (mavacamten) — REMS (NDA 214998 S-4)

Sponsor: BRISTOL. Class: REMS.

Trial startedJan 6, 2023· ClinicalTrials.gov

Phase 1 trial started: NCT05658146

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

2022

Trial registeredDec 20, 2022· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05658146

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Trial startedDec 14, 2022· ClinicalTrials.gov

Phase 3 trial started: NCT05582395

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

FDA approval (supplemental)Nov 22, 2022· FDA

FDA approved supplemental application for Camzyos (mavacamten) — REMS (NDA 214998 S-3)

Sponsor: BRISTOL. Class: REMS.

Trial registeredOct 17, 2022· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05582395

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Primary completionSep 11, 2022· ClinicalTrials.gov

Phase 1 primary completion: NCT05320094

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Trial startedAug 19, 2022· ClinicalTrials.gov

Phase 3 trial started: NCT05414175

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Primary completionAug 19, 2022· ClinicalTrials.gov

Phase 1 primary completion: NCT05362045

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Trial startedAug 16, 2022· ClinicalTrials.gov

Trial started: NCT05489705

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receivi

Results postedAug 9, 2022· ClinicalTrials.gov

Trial results posted: NCT03442764

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Trial registeredAug 5, 2022· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT05489705

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receivi

Trial registeredJun 10, 2022· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05414175

A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Trial startedMay 16, 2022· ClinicalTrials.gov

Phase 1 trial started: NCT05362045

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Trial registeredMay 5, 2022· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05362045

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

FDA approvalApr 28, 2022· FDA

FDA approved Camzyos (mavacamten) (NDA 214998)

Sponsor: BRISTOL. Class: Type 1 - New Molecular Entity.

Trial startedApr 15, 2022· ClinicalTrials.gov

Phase 1 trial started: NCT05320094

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Trial registeredApr 11, 2022· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05320094

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Primary completionFeb 7, 2022· ClinicalTrials.gov

Phase 3 primary completion: NCT04349072

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Primary completionFeb 5, 2022· ClinicalTrials.gov

Phase 1 primary completion: NCT05135871

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Trial startedJan 4, 2022· ClinicalTrials.gov

Phase 3 trial started: NCT05174416

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

2021

Trial registeredDec 30, 2021· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT05174416

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Trial registeredNov 26, 2021· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT05135871

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Trial startedOct 31, 2021· ClinicalTrials.gov

Phase 1 trial started: NCT05135871

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Results postedOct 4, 2021· ClinicalTrials.gov

Trial results posted: NCT03470545

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedMar 30, 2021· ClinicalTrials.gov

Phase 2 trial started: NCT04766892

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Trial registeredFeb 23, 2021· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT04766892

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

2020

Trial startedJul 6, 2020· ClinicalTrials.gov

Phase 3 trial started: NCT04349072

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Trial registeredApr 16, 2020· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT04349072

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Primary completionMar 14, 2020· ClinicalTrials.gov

Phase 3 primary completion: NCT03470545

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Primary completionJan 7, 2020· ClinicalTrials.gov

Phase 2 primary completion: NCT03442764

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

2018

Trial registeredOct 29, 2018· ClinicalTrials.gov

Phase 2/Phase 3 trial registered on ClinicalTrials.gov: NCT03723655

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Trial startedSep 27, 2018· ClinicalTrials.gov

Phase 2/Phase 3 trial started: NCT03723655

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Trial startedMay 29, 2018· ClinicalTrials.gov

Phase 3 trial started: NCT03470545

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial startedApr 26, 2018· ClinicalTrials.gov

Phase 2 trial started: NCT03496168

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Trial registeredApr 12, 2018· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03496168

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

Trial startedMar 30, 2018· ClinicalTrials.gov

Phase 2 trial started: NCT03442764

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Trial registeredMar 20, 2018· ClinicalTrials.gov

Phase 3 trial registered on ClinicalTrials.gov: NCT03470545

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial registeredFeb 22, 2018· ClinicalTrials.gov

Phase 2 trial registered on ClinicalTrials.gov: NCT03442764

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.